Kindeva Drug Delivery, a global drug delivery device CDMO, received a £33 million grant from the U.K. Government’s Life Sciences Innovation Manufacturing Fund (LSIMF) toward enhancing inhaler manufacturing and sustainability. The joint funds aim to enhance Kindeva’s capability and capacity to manufacture the next generation of green pressurized metered-dose inhalers (pMDIs) and to continue delivering evolving therapies for respiratory diseases.

The investment supports global development and manufacturing of inhalers using new, lower global warming potential (GWP) propellants, while creating local jobs across the company’s two U.K. sites — Loughborough and Clitheroe.

Additionally, this industry and government investment supports green improvements to Kindeva’s underlying inhaler componentry supply chain at the company’s Clitheroe site.

“This joint investment of public and private funds creates myriad new opportunities for Kindeva colleagues within the U.K., as significant technical and regulatory expertise is required in the development and manufacturing of complex inhalation products,” said Kindeva global chief commercial officer David Stevens. “This investment provides Kindeva with a springboard to expand our capabilities and capacity, while simultaneously partnering with leading pharmaceutical companies around the world to bring the next generation of green inhalers to market — with a common goal of safeguarding access to necessary therapies for patients and reducing our impact on the planet.”